...
首页> 外文期刊>Medicinal Chemistry Research >A facile synthesis of some 3-cyano-1,4,6-trisubstituted-2(1H)-pyridinones and their biological evaluation as anticancer agents
【24h】

A facile synthesis of some 3-cyano-1,4,6-trisubstituted-2(1H)-pyridinones and their biological evaluation as anticancer agents

机译:某些3-氰基-1,4,6-三取代-2(1H)-吡啶酮的简便合成及其作为抗癌药的生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

The synthesis of some new 3-cyano-1,4,6-trisubstituted-2(1H)-pyridinones supported with various pharmacophores and functionalities at positin-1 is described. The in vitro anticancer activity of 24 of the newly synthesized compounds was evaluated according to the protocol of the NCI in vitro disease-oriented human cells screening panel assay. The results revealed that five compounds 4a–c, 7b, and 12b were able to display moderate antitumor potential against some of the tested subpanel tumor cell lines at the GI50 and TGI levels, however, with marginal or no cytotoxic (LC50) activity. The obtained data suggested that better antitumor activity was linked to derivatives with either 4-bromophenyl or 3,4-dimethoxyphenyl moieties, together with a 1-methyl-1H-pyrrol-2-yl counter part at positions 6 and 4, respectively. Consequently, the 3-cyano-4-(1-methyl-1H-pyrrol-2-yl)-6-(4-bromophenyl or 3,4-dimethoxyphenyl)-2(1H)-pyridinones 4a and 4b, could be considered as the most active members identified in this investigation as evidenced from their relative higher growth inhibitory (GI50 (MG-MID) 77.6 and 67.6 μM, respectively) and cytostatic (TGI (MG-MID) 85.1 and 95.5 μM, respectively) activities, when compared with the substituted thiocarbamoyl analog 7b and the bicyclic [1,2,4]triazolo[3,4-a]pyridine derivative 12b.
机译:描述了一些新的3-氰基-1,4,6-三取代-2(1H)-吡啶并在positin-1上具有各种药效基团和官能团的合成。根据NCI面向疾病的体外人体细胞筛选实验的方法,评估了24种新合成化合物的体外抗癌活性。结果表明,在GI 50 和TGI水平下,五种化合物4a–c,7b和12b能够对某些测试的亚组肿瘤细胞系表现出中等的抗肿瘤潜能,但是边缘或没有细胞毒性(LC 50 )活性。获得的数据表明更好的抗肿瘤活性与具有4-溴苯基或3,4-二甲氧基苯基部分的衍生物以及分别在位置6和4处的1-甲基-1H-吡咯-2-基对位部分连接。因此,可以考虑3-氰基-4-(1-甲基-1H-吡咯-2-基)-6-(4-溴苯基或3,4-二甲氧基苯基)-2(1H)-吡啶酮4a和4b。作为本研究中确定的最活跃成员,从其相对较高的生长抑制因子(分别为GI 50 (MG-MID)77.6和67.6μM)和细胞生长抑制因子(TGI(MG-MID)85.1和与取代的硫代氨基甲酰基类似物7b和双环[1,2,4]三唑并[3,4-a]吡啶衍生物12b相比,活性分别为95.5μM)。

著录项

  • 来源
    《Medicinal Chemistry Research》 |2011年第8期|p.1260-1272|共13页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号